Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy. METHODS AND FINDINGS: 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of gemcitabine and erlotinib. Of 14 recruited subjects enrolled, nine completed the study (three in each dosage tier). There were fifteen non-serious adverse events and eight serious adverse events, all likely related to progression of disease or treatment with gemcitabine or erlotinib. Applying RECIST 1.0 criteria, seven of the nine subjects had stable disease while the other two had progressive disease. CONCLUSIONS: These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and erlotinib in pancreatic cancer patients. This, combined with the observed response to treatment, suggests the need for a phase II study of longer duration. TRIAL REGISTRATION: Clinicaltrials.gov NCT00954525.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Trials · doi:10.1186/1745-6215-11-32 · Cited by 1,871
Yeo, C. J., Cameron, J. L., Sohn, T. A., Lillemoe, K. D., Pitt, H. A., Talamini, M. A., Hruban, R. H., Ord, S. E., Sauter, P. K., Coleman, J., et al. (1997) · Annals of Surgery · doi:10.1097/00000658-199709000-00004 · Cited by 1,783
Self-citationVitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance
Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325
Self-citationChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075 · cited 4×
“and animal experiments, such pharmacologic concentrations of ascorbate kill a number of cancer cell types, but not normal cells, and decrease tumor growth in mice [14,15].”
BackgroundInfluentialSelf-citationVitamin C pharmacokinetics: Implications for oral and intravenous use
Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992
Self-citationKennedy, C. O. (1971) · British Homeopathic Journal · doi:10.1016/s0007-0785(71)80027-3 · Cited by 974
Research works printed but not linked: 3
- J Feliu, 2011, Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer., Cancer Chemother Pharmacol, 67, 215, 10.1007/s00280-010-1472-0 · doi:10.1007/s00280-010-1472-0
- A Ardavanis, 2009, Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer., Anticancer Res, 29, 5211
- MJ Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group., J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525 · DOI · Paper page
Cited by
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
Ascorbic acid: Chemistry, biology and the treatment of cancer
Du, J., Cullen, J. J., & Buettner, G. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.003 · Cited by 1,070
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501
Self-citationSchoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443
Welsh, J. L., Wagner, B. A., van’t Erve, T. J., Zehr, P. S., Berg, D. J., Halfdanarson, T. R., Yee, N. S., Bodeker, K. L., Du, J., Roberts, L. J., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2070-8 · Cited by 310
Self-citationTET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 273
Stephenson, C. M., Levin, R. D., Spector, T., & Lis, C. G. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2179-9 · Cited by 264
Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence
Vissers, M. C. M., & Das, A. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00809 · Cited by 188
“Some of these studies have suggested that high dose ascorbate treatment may have a clinical benefit for patients with pancreatic cancer (Monti et al., 2012; Cieslak and Cullen, 2015) and other advanced cancers (Hoffer et al.”
Kuiper, C., & Vissers, M. C. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00359 · Cited by 163
“In addition, a recent phase I clinical trial of high-dose intravenous ascorbate with gemcitabine and erlotinib in advanced pancreatic cancer has shown no adverse effects of including ascorbate (127).”
BackgroundIntravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge
Carr, A. C., & Cook, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01182 · Cited by 133
Intravenous Vitamin C and Cancer: A Systematic Review
Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., Skidmore, B., Kirchner, L., & Seely, D. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534463 · Cited by 124
“We included controlled and uncontrolled studies; controlled studies had to compare patients with cancer receiving IVC to patients with cancer not receiving IVC.”
BackgroundMethodResultInfluentialUpregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.65 · Cited by 111
Myths, Artifacts, and Fatal Flaws: Identifying Limitations and Opportunities in Vitamin C Research
Michels, A., & Frei, B. (2013) · Nutrients · doi:10.3390/nu5125161 · Cited by 111
“Further innovation has been demonstrated in studies on vitamin C bioavailability [69,108], metabolomics of vitamin C deficiency [137], genetic variation of the vitamin C transporters [103], and intravenous vitamin C infusions in cancer therapy [138,139].”
BackgroundSystematic Review of Intravenous Ascorbate in Cancer Clinical Trials
Nauman, G., Gray, J. C., Parkinson, R., Levine, M., & Paller, C. J. (2018) · Antioxidants · doi:10.3390/antiox7070089 · Cited by 107
Self-citationThe effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life
Carr, A. C., Vissers, M. C. M., & Cook, J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00283 · Cited by 104
Intravenous vitamin C in the supportive care of cancer patients: A review and rational approach
Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018) · Current Oncology · doi:10.3747/co.25.3790 · Cited by 99
Ma, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79
Manganoporphyrins Increase Ascorbate-Induced Cytotoxicity by Enhancing H2O2 Generation
Rawal, M., Schroeder, S. R., Wagner, B. A., Cushing, C. M., Welsh, J. L., Button, A. M., Du, J., Sibenaller, Z. A., Buettner, G. R., & Cullen, J. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0470 · Cited by 78
“In addition, phase I studies specifically in pancreatic cancer treatment have showed that pharmacologic ascorbate, combined with standard of care chemotherapy regimens, is safe and well tolerated and may lead to overall clinical benefit (9, 10).”
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model
Serrano, O. K., Parrow, N. L., Violet, P.-C., Yang, J., Zornjak, J., Basseville, A., & Levine, M. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.032 · Cited by 29
Self-citationThe interplay between vitamin C and thyroid
Farasati Far, B., Behnoush, A. H., Ghondaghsaz, E., Habibi, M. A., & Khalaji, A. (2023) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.432 · Cited by 23
Metadata
- Authors
- Monti, D. A., Mitchell, E., Bazzan, A. J., Littman, S., Zabrecky, G., Yeo, C. J., Pillai, M. V., Newberg, A. B., Deshmukh, S., & Levine, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-01-17
- Volume
- 7
- Issue
- 1
- Pages
- e29794
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2076098030
- Cited by
- 274
- References
- 33
- FWCI
- 9.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.